Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/42886
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBasheer, Neha-
dc.contributor.authorBuee, Luc-
dc.contributor.authorBrion, Jean-Pierre-
dc.contributor.authorSmolek, Tomas-
dc.contributor.authorMuhammadi, Muhammad Khalid-
dc.contributor.authorHritz, Jozef-
dc.contributor.authorHromadka, Tomas-
dc.contributor.authorDEWACHTER, Ilse-
dc.contributor.authorWegmann, Susanne-
dc.contributor.authorLandrieu, Isabelle-
dc.contributor.authorNovak, Petr-
dc.contributor.authorMudher, Amritpal-
dc.contributor.authorZilka, Norbert-
dc.date.accessioned2024-05-08T09:56:56Z-
dc.date.available2024-05-08T09:56:56Z-
dc.date.issued2024-
dc.date.submitted2024-05-08T09:37:47Z-
dc.identifier.citationActa Neuropathologica Communications, 12 (1) (Art N° 52)-
dc.identifier.urihttp://hdl.handle.net/1942/42886-
dc.description.abstractThe transcellular propagation of the aberrantly modified protein tau along the functional brain network is a key hallmark of Alzheimer's disease and related tauopathies. Inoculation-based tau propagation models can recapitulate the stereotypical spread of tau and reproduce various types of tau inclusions linked to specific tauopathy, albeit with varying degrees of fidelity. With this systematic review, we underscore the significance of judicious selection and meticulous functional, biochemical, and biophysical characterization of various tau inocula. Furthermore, we highlight the necessity of choosing suitable animal models and inoculation sites, along with the critical need for validation of fibrillary pathology using confirmatory staining, to accurately recapitulate disease-specific inclusions. As a practical guide, we put forth a framework for establishing a benchmark of inoculation-based tau propagation models that holds promise for use in preclinical testing of disease-modifying drugs.-
dc.description.sponsorshipFunding The present study received support from grants APVV-20–0447, APVV-190585, APVV-20-0331, JPND MULTI-MEMO, VEGA 2/0127/22, VEGA 2/0134/22 and European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska Curie grant agreement No 873127. Further sup‑ port for was extended through the European Union’s Horizon Europe program under the grant agreement No. 101087124. This publication refects only the author’s view, and the European Commission is not responsible for any use that may be made of the information it contains. Acknowledgements The authors wish to convey their heartfelt appreciation to the Rainwater Charitable foundation, the University of Lille and Région Hauts de France for endorsing the EuroTau meetings.-
dc.language.isoen-
dc.publisherBMC-
dc.rightsThe Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecom‑ mons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.-
dc.subject.otherTau protein-
dc.subject.otherPropagation-
dc.subject.otherSpreading-
dc.subject.otherAggregation-
dc.subject.otherNeurofibrillary tangles-
dc.subject.otherAnimal models-
dc.titleShaping the future of preclinical development of successful disease-modifying drugs against Alzheimer's disease: a systematic review of tau propagation models-
dc.typeJournal Contribution-
dc.identifier.issue1-
dc.identifier.volume12-
local.format.pages31-
local.bibliographicCitation.jcatA1-
dc.description.notesZilka, N (corresponding author), Slovak Acad Sci, Inst Neuroimmunol, Dubravska Cesta 9, Bratislava 84510, Slovakia.; Buee, L (corresponding author), Univ Lille, INSERM, CHU Lille, CNRS,LilNCog Lille Neurosci & Cognit, F-59000 Lille, France.; Zilka, N (corresponding author), AXON Neurosci R&D Serv SE, Dubravska Cesta 9, Bratislava 84510, Slovakia.-
dc.description.notesluc.buee@inserm.fr; norbert.zilka@savba.sk-
local.publisher.placeCAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND-
local.type.refereedRefereed-
local.type.specifiedReview-
local.bibliographicCitation.artnr52-
local.type.programmeH2020-
local.relation.h2020101087124-
dc.identifier.doi10.1186/s40478-024-01748-5-
dc.identifier.pmid38576010-
dc.identifier.isi001197175400001-
dc.contributor.orcidBUEE, Luc/0000-0002-6261-4230; Basheer, Neha/0000-0003-3669-3825-
local.provider.typewosris-
local.description.affiliation[Basheer, Neha; Smolek, Tomas; Muhammadi, Muhammad Khalid; Hromadka, Tomas; Novak, Petr; Zilka, Norbert] Slovak Acad Sci, Inst Neuroimmunol, Dubravska Cesta 9, Bratislava 84510, Slovakia.-
local.description.affiliation[Buee, Luc] Univ Lille, INSERM, CHU Lille, CNRS,LilNCog Lille Neurosci & Cognit, F-59000 Lille, France.-
local.description.affiliation[Brion, Jean-Pierre] Univ Libre Bruxelles, ULB Neurosci Inst UNI, Fac Med, Lab Histol,Alzheimer & Other Tauopathies Res Grp C, 808 Route Lennik, B-1070 Brussels, Belgium.-
local.description.affiliation[Hritz, Jozef] Masaryk Univ, CEITEC, Kamenice 5, Brno 62500, Czech Republic.-
local.description.affiliation[Hritz, Jozef] Masaryk Univ, Fac Sci, Dept Chem, Kamenice 5, Brno 62500, Czech Republic.-
local.description.affiliation[Dewachter, Ilse] Hasselt Univ, Biomed Res Inst, BIOMED, B-3500 Hasselt, Belgium.-
local.description.affiliation[Wegmann, Susanne] German Ctr Neurodegenerat Dis, Charitepl 1, D-10117 Berlin, Germany.-
local.description.affiliation[Wegmann, Susanne] Charite Univ Med Berlin, Einstein Ctr Neurosci Berlin, Berlin, Germany.-
local.description.affiliation[Landrieu, Isabelle] CNRS, EMR9002, BSI Integrat Struct Biol, F-59000 Lille, France.-
local.description.affiliation[Landrieu, Isabelle] Univ Lille, Inst Pasteur Lille, INSERM, CHU Lille,U1167 RID AGE Risk Factors & Mol Determi, F-59000 Lille, France.-
local.description.affiliation[Mudher, Amritpal] Univ Southampton, Fac Environm & Life Sci, Sch Biol Sci, Highfield Campus, Southampton SO17 1BJ, England.-
local.description.affiliation[Zilka, Norbert] AXON Neurosci R&D Serv SE, Dubravska Cesta 9, Bratislava 84510, Slovakia.-
local.uhasselt.internationalyes-
item.fullcitationBasheer, Neha; Buee, Luc; Brion, Jean-Pierre; Smolek, Tomas; Muhammadi, Muhammad Khalid; Hritz, Jozef; Hromadka, Tomas; DEWACHTER, Ilse; Wegmann, Susanne; Landrieu, Isabelle; Novak, Petr; Mudher, Amritpal & Zilka, Norbert (2024) Shaping the future of preclinical development of successful disease-modifying drugs against Alzheimer's disease: a systematic review of tau propagation models. In: Acta Neuropathologica Communications, 12 (1) (Art N° 52).-
item.accessRightsOpen Access-
item.fulltextWith Fulltext-
item.contributorBasheer, Neha-
item.contributorBuee, Luc-
item.contributorBrion, Jean-Pierre-
item.contributorSmolek, Tomas-
item.contributorMuhammadi, Muhammad Khalid-
item.contributorHritz, Jozef-
item.contributorHromadka, Tomas-
item.contributorDEWACHTER, Ilse-
item.contributorWegmann, Susanne-
item.contributorLandrieu, Isabelle-
item.contributorNovak, Petr-
item.contributorMudher, Amritpal-
item.contributorZilka, Norbert-
crisitem.journal.issn2051-5960-
crisitem.journal.eissn2051-5960-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
s40478-024-01748-5.pdfPublished version2.29 MBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.